These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7503060)

  • 1. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Sadjadi SA
    Am J Kidney Dis; 1995 Dec; 26(6):1000-1. PubMed ID: 7503060
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Perazella MA
    Am J Kidney Dis; 1995 Dec; 26(6):1000; author reply 1001. PubMed ID: 7503059
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance and use of iron supplementation in uremia.
    Makoff R
    Nephrol News Issues; 1992 Jun; 6(6):14-6, 19. PubMed ID: 1608475
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correction of anemia in hemodialysis, effect of intravenous iron without erythropoietin].
    Alvo M; Elgueta L; Aragón H; Cotera A
    Rev Med Chil; 2002 Aug; 130(8):865-8. PubMed ID: 12360794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
    Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
    Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
    Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin can be administered during dialysis. A kinetic analysis.
    Petersen J; Kang MS; Hays MT
    ASAIO J; 1996; 42(1):27-33. PubMed ID: 8808454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of intravenous iron in chronic renal patients with anemia. Higher levels of hemoglobin at a lower cost].
    Cuero CJ; Pérez E; de Rivera C
    Rev Med Panama; 1998; 23(1):14-6. PubMed ID: 10997188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from NKF-DOQI: iron management.
    Van Wyck DB
    Semin Nephrol; 2000 Jul; 20(4):330-4. PubMed ID: 10928334
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous blood donation with recombinant human erythropoietin in cardiac surgery: the Japanese experience.
    Baron JF
    Semin Hematol; 1996 Apr; 33(2 Suppl 2):64-7; discussion 68. PubMed ID: 8723586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supervised intradialytic oral iron administration during erythropoietin therapy.
    Fourtounas C; Koutsikos D; Dalamangas A; Kapetanaki A; Kostoglou M; Agroyannis B; Tzanatos H; Kopelias I; Bosiolis B
    Nephrol Dial Transplant; 1996 Jul; 11(7):1485-6. PubMed ID: 8815424
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
    Garneata L
    J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
    Svára F; Sulková S; Kvasnićka J; Polakovic V
    Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.